Browsing by Author "Murmu, Masang"

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Clinical potential of long non-coding RNA LINC01133 as a promising biomarker and therapeutic target in cancers
    (Newlands Press Ltd, 2022-02-23T00:00:00) Sharma, Uttam; Barwal, Tushar Singh; Murmu, Masang; Acharya, Varnali; Pant, Neha; Dey, Damayanti; Vivek; Gautam, Ashima; Bazala, Sonali; Singh, Ipsa; Azzouz, Farah; Bishayee, Anupam; Jain, Aklank
    Recently, long intergenic non-protein coding RNA 01133 (LINC01133) was identified as a novel transcript in cancers. It modulates various hallmarks of cancers and acts as oncogenic in some cancers while tumor-suppressive in others. Furthermore, the expression of LINC01133 correlates with tumor size, advanced tumor node metastasis stage and lymphatic node metastasis, Ki-67 levels and overall survival of patients. Herein, the authors provide an in-depth analysis describing how LINC01133 modulates the multiple cancer-associated signaling pathways and the pathogenesis of various malignancies and treatment regimens. Based on the role played by LINC01133, the authors propose LINC01133 as both a potential biomarker and a therapeutic target in cancer. � 2022 Future Medicine Ltd.
  • No Thumbnail Available
    Item
    A Pleiotropic Role of Long Non-Coding RNAs in the Modulation of Wnt/?-Catenin and PI3K/Akt/mTOR Signaling Pathways in Esophageal Squamous Cell Carcinoma: Implication in Chemotherapeutic Drug Response
    (MDPI, 2022-03-28T00:00:00) Sharma, Uttam; Murmu, Masang; Barwal, Tushar Singh; Tuli, Hardeep Singh; Jain, Manju; Prakash, Hridayesh; Kaceli, Tea; Jain, Aklank; Bishayee, Anupam
    Despite the availability of modern techniques for the treatment of esophageal squamous cell carcinoma (ESCC), tumor recurrence and metastasis are significant challenges in clinical management. Thus, ESCC possesses a poor prognosis and low five-year overall survival rate. Notably, the origin and recurrence of the cancer phenotype are under the control of complex cancer-related signaling pathways. In this review, we provide comprehensive knowledge about long non-coding RNAs (lncRNAs) related to Wnt/?-catenin and phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling pathway in ESCC and its implications in hindering the efficacy of chemotherapeutic drugs. We observed that a pool of lncRNAs, such as HERES, TUG1, and UCA1, associated with ESCC, directly or indirectly targets various molecules of the Wnt/?-catenin pathway and facilitates the manifestation of multiple cancer phenotypes, including proliferation, metastasis, relapse, and resistance to anticancer treatment. Additionally, several lncRNAs, such as HCP5 and PTCSC1, modulate PI3K/Akt/mTOR pathways during the ESCC pathogenesis. Furthermore, a few lncRNAs, such as AFAP1-AS1 and LINC01014, block the efficiency of chemotherapeutic drugs, including cisplatin, 5-fluorouracil, paclitaxel, and gefitinib, used for ESCC treatment. Therefore, this review may help in designing a better therapeutic strategy for ESCC patients. � 2022 by the authors. Licensee MDPI, Basel, Switzerland.
  • No Thumbnail Available
    Item
    Potential clinical application of lncRNAs in pediatric cancer
    (Elsevier, 2022-01-28T00:00:00) Chhabra, Ravindresh; Neyol, Priyasha; Bazala, Sonali; Singh, Ipsa; Murmu, Masang; Sharma, Uttam; Barwal, Tushar Singh; Jain, Aklank
    Cancer is the leading cause of death by disease in children globally. The childhood cancer burden is more than 80% in the low- and middle-income countries, including India. In contrast to cancer in adults, the number of children diagnosed with cancer is far less but the children who survive cancer are more likely to face the negative consequences of chemotherapy and radiotherapy in their lifetime. The common childhood cancers include leukemia, neuroblastoma, osteosarcoma, retinoblastoma, rhabdomyosarcoma, and Wilms tumor. Long noncoding RNAs (lncRNAs) are a pervasive subset of noncoding RNAs. The high throughput sequencing studies estimate the number of lncRNAs to be more than 100, 000 but hardly 1% of them have been functionally characterized. The lncRNAs have a tissue-specific expression and a majority of them are functionally dysregulated in numerous physiological and pathological conditions, including cancer, thereby making them attractive therapeutic targets. Recently, their role has also been described in pediatric cancers. This chapter summarizes the current knowledge about dysregulated lncRNAs, their potential as biomarker and therapeutic targets, and their underlying molecular mechanisms in pediatric cancer. � 2022 Elsevier Inc. All rights reserved.